Aclaris Therapeutics, Inc.
ACRS
$6.18
$0.162.66%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -75.74M | -69.66M | -64.92M | -141.68M | -134.65M |
| Total Depreciation and Amortization | 421.00K | 428.00K | 454.00K | 495.00K | 564.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 12.46M | 14.05M | 14.68M | 99.82M | 100.67M |
| Change in Net Operating Assets | 802.00K | 2.98M | 2.67M | -1.56M | 23.43M |
| Cash from Operations | -62.06M | -52.21M | -47.11M | -42.92M | -9.99M |
| Capital Expenditure | -118.00K | -81.00K | -111.00K | -87.00K | -64.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 3.65M | -1.61M | 48.48M | -50.64M | -61.70M |
| Cash from Investing | 3.53M | -1.69M | 48.37M | -50.73M | -61.76M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 58.15M | 58.03M | -- | 80.00M | 80.03M |
| Repurchase of Common Stock | -435.00K | -421.00K | -446.00K | -617.00K | -627.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -5.42M | -5.42M | -5.42M | -8.13M | -5.09M |
| Cash from Financing | 52.29M | 52.19M | -5.86M | 71.25M | 74.32M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -6.24M | -1.70M | -4.61M | -22.40M | 2.57M |